Neuron-Specific Enhancer for Cholinergic Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as ALS and Alzheimer's are limited, and existing gene therapy approaches face challenges in achieving neuron-specific and temporally-controlled gene expression.
Innovation Solution
Development of an enhancer specific to a subset of cholinergic neurons, including motor neurons, that can control gene expression in a highly neuron-specific and temporally-controlled manner, using a nucleic acid comprising an enhancer sequence and a nucleotide sequence encoding a polypeptide or oligonucleotide of interest.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If broad expression of transgenes or knockdown constructs is used in gene therapy, then therapeutic coverage is improved, but deleterious side effects increase
Solution Approach 1:
The patent applies local quality by using cell-type-specific promoters (HB9 for motor neurons, SL6 for basal forebrain cholinergic neurons) to restrict transgene expression to specific neuronal populations. This ensures therapeutic action is localized to target cells while avoiding off-target effects in other tissues, thereby maintaining therapeutic coverage while reducing harmful side effects.
Solution Approach 2:
The patent segments the therapeutic approach by creating separate gene therapy constructs for different neuronal types (motor neurons vs. basal forebrain cholinergic neurons). Each construct uses tissue-specific regulatory elements to independently control expression in the intended target population, allowing precise spatial segmentation of therapeutic effects.
2Manufacturing precision
If neuron-specific gene expression is achieved using existing promoters, then specificity is improved, but temporal control capability deteriorates
Solution Approach 1:
The patent implements dynamics by incorporating the tetracycline-responsive element (TRE) into the promoter constructs, enabling the expression system to dynamically respond to external doxycycline administration. This allows temporal control of gene expression in already neuron-specific cell types, converting a static expression system into a dynamically controllable one without sacrificing cellular specificity.
Solution Approach 2:
The patent uses doxycycline as an intermediary molecule to control gene expression temporally. The tetracycline-responsive element in the promoter allows doxycycline to act as a mediator that can induce or repress transcription in target neurons, providing external temporal control while maintaining endogenous neuron-specificity through the tissue-specific promoter components.
Data Source
AI summary
The subject matter described here relates to an enhancer specific to a subset of cholinergic neurons, that can control gene expression in a highly neuron-specific manner, wherein the enhancer is compatible with AAVs packaging and can induce gene expression or knockdown in cholinergic neurons in both post-natal and adult subjects.